Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
Protocol # 21-245

Status

Recruiting

Description

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered according to different dosing schedules as a single agent and in combination with dexamethasone.

Condition

  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin's

Interventions

  • CFT7455
  • Dexamethasone Oral

Phase

Phase 1/Phase 2

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Phase 1: Safety and tolerability of CFT7455
  • Phase 1: Safety and tolerability of CFT7455 for CFT7455 in combination with dexamethasone
  • Phase 1: Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for CFT7455
  • Phase 1: MTD or recommended RP2D for CFT7455 in combination with dexamethasone
  • Phase 2: Antitumor activity of CFT7455
  • Phase 2: Antitumor activity of CFT7455 in combination with dexamethasone

Enrollment

158

Study Start Date

April 27, 2021

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

C4 Therapeutics, Inc.

Source

C4 Therapeutics, Inc.

Official title

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Clinicaltrials.gov Identifier

NCT04756726

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.